Posted 3/28/2024, 3:50:08 PM
FDA Approves New Anemia Drug Vafseo for Dialysis Patients with Chronic Kidney Disease
- FDA approves Akebia Therapeutics' Vafseo to treat anemia in dialysis patients with chronic kidney disease
- Vafseo is a once-daily oral medication that stimulates production of erythropoietin
- Approved in 37 countries, including the U.S. based on clinical trial and safety data
- Approximately 500,000 U.S. dialysis patients suffer from kidney disease-associated anemia
- Akebia intends to commercialize Vafseo in the U.S. with goal of becoming standard of care
